Arrow-right Camera

The Spokesman-Review Newspaper The Spokesman-Review

Friday, November 22, 2019  Spokane, Washington  Est. May 19, 1883
Partly Cloudy Day 32° Partly Cloudy
News >  Business

EpiPen manufacturer will be a no-show at Senate hearing

In this July 8 file photo, a pharmacist holds a package of EpiPen epinephrine auto-injectors, a Mylan product, in Sacramento, Calif. (Rich Pedroncelli / Associated Press)
In this July 8 file photo, a pharmacist holds a package of EpiPen epinephrine auto-injectors, a Mylan product, in Sacramento, Calif. (Rich Pedroncelli / Associated Press)
By Mary Clare Jalonick Associated Press

WASHINGTON – Senate Judiciary Chairman Charles Grassley says pharmaceutical company Mylan is declining to testify at his committee’s hearing next week on a settlement between the company and the Justice Department over its life-saving Epi-Pen.

Grassley on Monday released a letter from an attorney for Mylan saying officials would not testify. The Nov. 18 letter said company executives wouldn’t testify because the settlement is a pending matter and the Justice Department would also not be attending.

Mylan will pay $465 million to settle allegations that it overbilled Medicaid for EpiPen. At issue was whether the product should have been classified as generic under a Medicaid program.

The list price of EpiPens had grown to $608 for a two-pack, an increase of more than 500 percent since 2007.

Subscribe to the Morning Review newsletter

Get the day’s top headlines delivered to your inbox every morning by subscribing to our newsletter.

You have been successfully subscribed!
There was a problem subscribing you to the newsletter. Double check your email and try again, or email webteam@spokesman.com